Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Worksite Healthy Pregnancy Program Improves Health Behaviors
Dudley, Tiffany J., Ahrens, Desiree J., Friend, Jamie L., Jenkins, Sarah M. , Nelson, Nancy C., Borowski, Kristi, Clark, Matthew M. , Friend, Jamie L., Nelson, Nancy C.

Mayo Clinic

Health Behavior and Policy Review | February 5, 2019 | Volume: 5 | Issue: 3 | Pages: 50-58

10.14485/hbpr.5.3.5 Get It

Abstract A015: Molecular tumor profiling to identify mechanisms linking statin use with lower risk of lethal prostate cancer: Results from the Health Professionals Follow-up Study
Gonzalez‐Feliciano, Amparo G., Wilson, Kathryn M. , Gerke, Travis , Downer, Mary K. , Freedland, Stephen J. , Stampfer, Meir J. , Giovannucci, Edward L. , Mucci, Lorelei A. , Allott, Emma H. , Ebot, Ericka M. , Markt, Sarah Coseo , Ahearn, Thomas U. , Stopsack, Konrad H. , Rider, Jennifer R. , Platz, Elizabeth A. , Sweeney, Christopher J. , Finn, Stephen P.

Mayo Clinic

Cancer Research | February 4, 2019 | Volume: 78 | Issue: 16_Supplement | Pages: A015-A015

10.1158/1538-7445.prca2017-a015 Get It

Abstract Introduction: Epidemiologic data support an inverse association between statin use and risk of lethal prostate cancer, but contributing mechanisms have not been elucidated. Herein, using data from the Health Professionals Follow-up Study (HPFS), we updated our previous analysis of statins and lethal prostate cancer with a decade of additional follow-up, and incorporated immunohistochemistry (IHC)-based biomarkers and gene expression profiling to identify putative molecular mechanisms contributing to the association. Methods: We included data from 44,076 HPFS participants who were cancer free in 1990, with follow-up through 2012. Participants reported prediagnostic statin use on biennial questionnaires. Statin use was categorized as current vs. never/past use, with current users further categorized as long-term vs. short-term users (≥6 vs. <6 years). To classify prostate cancer molecular subtypes, genetically validated IHC assays for TMPRSS2:ERG fusion and PTEN loss were conducted on tissue microarrays for 891 and 660 cases, respectively. Whole-genome mRNA profiling of tumor and adjacent normal tissue was completed for 237 and 114 cases, respectively, using Affymetrix GeneChip Human Gene 1.0 ST arrays. We used Cox proportional hazards analysis to generate hazard ratios (HR) and 95% confidence intervals (CI) for associations between statin use and risk of overall, advanced (stage T3b or higher at diagnosis, metastatic or fatal), and lethal (metastatic or fatal) prostate cancer, as well as molecular subtypes, adjusted for PSA testing behavior and potential confounders including obesity and smoking. Moreover, we explored gene expression pathways in tumor and adjacent normal prostate tissue of statin users vs. nonusers using gene set enrichment analysis (GSEA). Results: During 22 years of follow-up, 6,144 men were diagnosed with prostate cancer; 1,051 (17%) had advanced disease and 827 (13%) developed lethal prostate cancer. Of cases with molecular subtype available, 48% were ERG-positive and 14% PTEN-null. In multivariable analysis, relative to never/past use, current statin use was inversely associated with risk of advanced (HR 0.84; 95% CI 0.68-1.04) and lethal (HR 0.78; 95% CI 0.68-1.01) prostate cancer. These associations were more pronounced in long-term users, where ≥6 years of prediagnosis statin use was significantly associated with a lower risk of advanced (HR 0.72; 95% CI 0.53-0.97) and lethal prostate cancer (HR 0.64; 95% CI 0.45-0.92), relative to nonuse. Long-term statin use was not associated with overall prostate cancer risk, whether ERG-positive (HR 0.89; 95% CI 0.59-1.35) or ERG-negative (HR 1.06; 95% CI 0.74-1.50). However, relative to nonuse, a longer duration of prediagnosis statin use was associated with reduced risk of PTEN-null cancers (HR 0.42; 95% CI 0.20-0.90), but not PTEN-intact disease (HR 1.18; 95% CI 0.95-1.46; p-heterogeneity=0.01). In GSEA, we identified T cell, B cell, and phosphatidylinositol (PI3K) signaling among the top pathways enriched in tumor-adjacent normal prostate tissue of current statin users, relative to never users. Intriguingly, no gene sets were differentially expressed by statin use in the tumor. Discussion: Our updated findings from the HPFS are consistent with our prior findings and other epidemiologic data supporting a role for statins in lethal prostate cancer prevention. Molecular classification of tumors identified PTEN/PI3K signaling and inflammation/immune activation as two potential mechanisms contributing to this association. Elucidating molecular mechanisms mediating the association between statin use and lower risk of lethal prostate cancer will provide support for a causal effect of statins on lethal prostate cancer risk and could inform statin clinical trials with appropriate intermediate endpoints. Citation Format: Emma H. Allott, Ericka M. Ebot, Amparo G. Gonzalez-Feliciano, Sarah C. Markt, Kathryn M. Wilson, Thomas U. Ahearn, Travis A. Gerke, Mary K. Downer, Konrad H. Stopsack, Jennifer R. Rider, Stephen J. Freedland, Elizabeth A. Platz, Meir J. Stampfer, Edward L. Giovannucci, Christopher J. Sweeney, Stephen P. Finn, Lorelei A. Mucci. Molecular tumor profiling to identify mechanisms linking statin use with lower risk of lethal prostate cancer: Results from the Health Professionals Follow-up Study [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A015.
Chronic Pancreatitis
Schwarzenberg, Sarah Jane , Uç, Aliye , Zimmerman, Bridget, Wilschanski, Michael , Wilcox, C. Mel , Werlin, Steven L. , Troendle, David M. , Tang, Gong , Slivka, Adam, Sherman, Stuart , Shah, Uzma , Sandhu, Bimaljit S., Romagnuolo, Joseph , Rhee, Sue, Pohl, John F. , Perito, Emily R. , Ooi, Chee Y. , Nathan, Jaimie D. , Muniraj, Thiruvengadam , Morinville, Véronique D., McFerron, Brian A. , Mascarenhas, Maria R., Maqbool, Asim , Liu, Quin , Lin, Tom K. , Lewis, Michele D. , Husain, Sohail Z. , Heyman, Melvin B. , Guda, Nalini M. , Gonska, Tanja , Giefer, Matthew J. , Gelrud, Andrés , Gariepy, Cheryl E. , Gardner, Timothy B. , Freedman, Steven D., Forsmark, Christopher E., Fishman, Douglas S., Coté, Gregory A. , Conwell, Darwin L. , Barth, Bradley, Banks, Peter A. , Anderson, Michelle A. , Amann, Stephen T. , Alkaade, Samer, Abu‐El‐Haija, Maisam , Abberbock, Judah , Lowe, Mark E. , Yadav, Dhiraj , Lewis, Michele, Lewis, Michele D , Whitcomb, David C. , Singh, Vikesh K. , Himes, Ryan , Brand, Randall E. , Bellin, Melena D.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 2, 2019 | Volume: 68 | Issue: 4 | Pages: 566-573

10.1097/mpg.0000000000002279 | PMID 30897605 Get It

ABSTRACTObjectives:The aim of the present study was to investigate the natural history of chronic pancreatitis (CP); patients in the North American Pancreatitis Study2 (NAPS2, adults) and INternational Study group of Pediatric Pancreatitis: In search for a cuRE (INSPPIRE, pediatric) were compared.Methods:Demographics, risk factors, disease duration, management and outcomes of 224 children and 1063 adults were compared using appropriate statistical tests for categorical and continuous variables.Results:Alcohol was a risk in 53% of adults and 1% of children (P < 0.0001); tobacco in 50% of adults and 7% of children (P < 0.0001). Obstructive factors were more common in children (29% vs 19% in adults, P = 0.001). Genetic risk factors were found more often in children. Exocrine pancreatic insufficiency was similar (children 26% vs adult 33%, P = 0.107). Diabetes was more common in adults than children (36% vs 4% respectively, P < 0.0001). Median emergency room visits, hospitalizations, and missed days of work/school were similar across the cohorts. As a secondary analysis, NAPS2 subjects with childhood onset (NAPS2‐CO) were compared with INSPPIRE subjects. These 2 cohorts were more similar than the total INSPPIRE and NAPS2 cohorts, including for genetic risk factors. The only risk factor significantly more common in the NAPS2‐CO cohort compared with the INSPPIRE cohort was alcohol (9% NAPS2‐CO vs 1% INSPPIRE cohorts, P = 0.011).Conclusions:Despite disparity in age of onset, children and adults with CP exhibit similarity in demographics, CP treatment, and pain. Differences between groups in radiographic findings and diabetes prevalence may be related to differences in risk factors associated with disease and length of time of CP.
The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality
Horsley‐Silva, Jennifer L. , Umar, Sarah B. , Vela, Marcelo F. , Griffing, W. Leroy , Parish, James M., DiBaise, John K. , Crowell, Michael D.

Mayo Clinic

Diseases of the Esophagus | February 1, 2019 | Volume: 32 | Issue: 5 | Pages: No page available

10.1093/dote/doy136 | PMID 30715227 Get It

Caveolae, caveolin-1 and lung diseases of aging
Wicher, Sarah A. , Prakash, Y. S. , Prakash, Y S , Pabelick, Christina M.

Mayo Clinic

Expert Review of Respiratory Medicine | January 28, 2019 | Volume: 13 | Issue: 3 | Pages: 291-300

10.1080/17476348.2019.1575733 | PMID 30686114 Get It

Comparison of Surgeon Performance of Rotator Cuff Repair
Thigpen, Charles A. , Chapman, Cole G. , Tokish, John M. , Kissenberth, Michael J. , Hawkins, Richard J. , Brooks, John M. , Floyd, Sarah B.

Mayo Clinic

Journal of Bone and Joint Surgery | January 26, 2019 | Volume: 100 | Issue: 24 | Pages: 2110-2117

10.2106/jbjs.18.00211 | PMID 30562291 Get It

Background: Movement toward a value-based health-care system necessitates the development of performance measures to compare physicians, hospitals, and health-care systems. Patient-reported outcomes (PROs) are a potential metric. However, valid use of PROs hinges on the ability to risk-adjust for baseline patient differences across a surgeon’s panel of patients. The purpose of this study was to propose an approach for baseline risk adjustment and evaluate the importance of risk adjustment when comparing surgeons’ performance of rotator cuff repair. Methods: Patients (n = 995) treated with arthroscopic rotator cuff repair by 34 surgeons from 2010 to 2017 were identified from a large sports medicine clinical data registry. A linear regression model was used to adjust for baseline PROs, patient demographics, and clinical characteristics to predict American Shoulder and Elbow Surgeons (ASES) change scores for each surgeon. A risk-adjusted performance measure was calculated as the difference between the average unadjusted ASES change scores and the risk-adjusted predicted ASES change scores across all patients treated by a surgeon. Results: The differences between unadjusted and risk-adjusted performance scores varied widely across surgeons (range, −13.8 to 10.3 ASES points). Use of the risk-adjusted performance scores resulted in a dramatic change in the relative ranking of surgeons, compared with the ranking based on the observed ASES change scores, with 31 of the 34 surgeons’ rank changing following risk adjustment. On average, the observed ASES scores improved from 49.5 ± 17.5 at baseline to 78.0 ± 22.5 at 6 months across all surgeons. In the risk-adjustment model (R 2 = 0.44), male sex, Workers’ Compensation status, higher scores on the Veterans RAND 12-item Health Survey (VR-12), lower baseline ASES scores, fair and poor tendon quality, and night pain all had a significant effect on the predicted ASES change scores (p < 0.05). Conclusions: Our results show wide variation of nearly 25 points in the risk-adjusted 6-month ASES performance difference from the highest to the lowest-performing surgeons. Additionally, 91% of surgeons’ rank changed following risk adjustment. This suggests that performance measurement that does not account for baseline patient characteristics would likely result in incorrect conclusions about a surgeon’s relative performance based on PROs. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
Ross, Joseph S. , Rohde, Stefanie , Sangaralingham, Lindsey R. , Brito, Juan P. , Choi, Lauren , Graham, David J. , Jenkins, Marjorie , Mendoza, Martín, Qiang, Yandong, Wang, Zhong , Wu, Yute, Shah, Nilay D. , Sangaralingham, Lindsey, Yao, Xiaoxi , Ross, Joseph S , Brito, Juan P , Dutcher, Sarah K. , Lipska, Kasia J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 25, 2019 | Volume: 104 | Issue: 6 | Pages: 2305-2314

10.1210/jc.2018-02197 | PMID 30690529 Get It

Reply to Lutz-Bonengel et al.: Biparental mtDNA transmission is unlikely to be the result of nuclear mitochondrial DNA segments
Luo, Shiyu , Valencia, C. Alexander , Lee, Ni‐Chung , Slone, Jesse , Gui, Baoheng , Wang, Xinjian , Dell, Sarah, Brown, Jenice, Chen, Stella Maris, Hwu, Wuh‐Liang , Fan, Pi‐Chuan , Wong, Lee‐Jun C. , Huang, Taosheng , Li, Zhuo , Zhang, Jinglan , Li, Zhuo , Chien, Yin-Hsiu , Atwal, Paldeep S

Mayo Clinic

Proceedings of the National Academy of Sciences | January 23, 2019 | Volume: 116 | Issue: 6 | Pages: 1823-1824

10.1073/pnas.1821357116 | PMID 30674682 Get It

Optical coherence tomography is highly sensitive in detecting prior optic neuritis
Xu, Sarah Chaoying, Kardon, Randy H. , Leavitt, Jacqueline A., Pittock, Sean J. , Chen, John J. , Pittock, S J , Chen, John J , Flanagan, Eoin P.

Mayo Clinic

Neurology | January 23, 2019 | Volume: 92 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000006873 | PMID 30674600 Get It